Literature DB >> 17883361

Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial.

Douglas J E Schuerer1, Jeanne E Zack, James Thomas, Ingrid B Borecki, Carrie S Sona, Marilyn E Schallom, Melissa Venker, Jennifer L Nemeth, Myrna R Ward, Linda Verjan, David K Warren, Victoria J Fraser, John E Mazuski, Walter A Boyle, Timothy G Buchman, Craig M Coopersmith.   

Abstract

BACKGROUND: Current guidelines recommend using antiseptic- or antibiotic-impregnated central venous catheters (CVCs) if, following a comprehensive strategy to prevent catheter-related blood stream infection (CR-BSI), infection rates remain above institutional goals based on benchmark values. The purpose of this study was to determine if chlorhexidine/silver sulfadiazine-impregnated CVCs could decrease the CR-BSI rate in an intensive care unit (ICU) with a low baseline infection rate.
METHODS: Pre-intervention and post-intervention observational study in a 24-bed surgical/trauma/burn ICU from October, 2002 to August, 2005. All patients requiring CVC placement after March, 2004 had a chlorhexidine/silver sulfadiazine-impregnated catheter inserted (post-intervention period).
RESULTS: Twenty-three CR-BSIs occurred in 6,960 catheter days (3.3 per 1,000 catheter days)during the 17-month control period. After introduction of chlorhexidine/silver sulfadiazine-impregnated catheters, 16 CR-BSIs occurred in 7,732 catheter days (2.1 per 1,000 catheter days; p = 0.16). The average length of time required for an infection to become established after catheterization was similar in the two groups (8.4 vs. 8.6 days; p = 0.85). Chlorhexidine/silver sulfadiazine-impregnated catheters did not result in a statistically significant change in the microbiological profile of CR-BSIs, nor did they increase the incidence of resistant organisms.
CONCLUSIONS: Although chlorhexidine/silver sulfadiazine-impregnated catheters are useful in specific patient populations, they did not result in a statistically significant decrease in the CR-BSI rate in this study, beyond what was achieved with education alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17883361     DOI: 10.1089/sur.2006.073

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  8 in total

1.  On the way towards eradication of catheter-related infections!

Authors:  Philippe Eggimann; Giorgio Zanetti
Journal:  Intensive Care Med       Date:  2008-03-04       Impact factor: 17.440

2.  Development of Gendine-Coated Cannula for Continuous Subcutaneous Insulin Infusion for Extended Use.

Authors:  Mohamed A Jamal; Kumait Garoge; Joel S Rosenblatt; Ray Y Hachem; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

3.  In vivo biocompatibility and in vitro efficacy of antimicrobial gendine-coated central catheters.

Authors:  Mohamed A Jamal; Ray Y Hachem; Joel Rosenblatt; Mark J McArthur; Edd Felix; Ying Jiang; Ramesh C Tailor; Issam Raad
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

Review 4.  Use of silver in the prevention and treatment of infections: silver review.

Authors:  Amani D Politano; Kristin T Campbell; Laura H Rosenberger; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2013-02-28       Impact factor: 2.150

5.  Antimicrobial chlorhexidine/silver sulfadiazine-coated central venous catheters versus those uncoated in patients undergoing allogeneic stem cell transplantation.

Authors:  Samuel Vokurka; Klara Kabatova-Maxova; Jana Skardova; Eva Bystricka
Journal:  Support Care Cancer       Date:  2008-05-01       Impact factor: 3.603

Review 6.  Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults.

Authors:  Nai Ming Lai; Nathorn Chaiyakunapruk; Nai An Lai; Elizabeth O'Riordan; Wilson Shu Cheng Pau; Sanjay Saint
Journal:  Cochrane Database Syst Rev       Date:  2016-03-16

Review 7.  The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review.

Authors:  Ruth A Reitzel; Joel Rosenblatt; Bahgat Z Gerges; Andrew Jarjour; Ana Fernández-Cruz; Issam I Raad
Journal:  JAC Antimicrob Resist       Date:  2020-02-21

Review 8.  The Impact of Engineered Silver Nanomaterials on the Immune System.

Authors:  Neethu Ninan; Nirmal Goswami; Krasimir Vasilev
Journal:  Nanomaterials (Basel)       Date:  2020-05-18       Impact factor: 5.719

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.